Lyme disease is North America’s most frequent vector illness. The etiological agent is the Borreliella burgdorferi spirochete, transmitted via the Ixodes tick to mammalian hosts. The number of instances of Lyme disease has increased in recent years. No human vaccination is currently available on the market. The development of a new DNA vaccine with synthesis pLD1 is described as aimed towards Borreliella burgdorferi’s surface protein A (OspA). The immunisation of C3 H/HeN mice with pLD1 gives the bacterial challenge to Borreliella burgdorferi powerful humorous and cellular immunologies.

The study also analysed the administration of pLD1 intradermal (ID) to Hartley guinea pigs, showing robust and lasting humoral immunity induced for at least 1 year. They highlighted the potential of pLD1 by showing that the immunised guinea pigs are significantly treated by anticuerpos aimed at OspA epitopes that are connected to protection. The study discussed provides the basis for pDL1 as a possible vaccination for controlling Lyme disease.

Reference: https://www.tandfonline.com/doi/full/10.1080/21645515.2020.1789408